CooperVision Showcases Innovative Research at 2026 NCC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy COO?
Source: PRnewswire
- Research Presentation: CooperVision will showcase multiple studies at the 2026 Netherlands Contact Lens Congress, emphasizing how evidence-based care and continuous innovation promote the use of transparent and comfortable contact lenses, which is expected to elevate industry standards and enhance customer trust.
- Adaptation Study: One study reveals that young adults transitioning from single-vision lenses to the MiSight® 1 day dual-focus design report comparable vision quality and comfort within six months, highlighting the importance of professionals managing patient expectations during the adaptation period.
- Multifocal Lens Research: CooperVision's research also explores the adaptation of multifocal lenses, finding proactive adaptation opportunities for early presbyopia patients and better alignment with adaptation guidelines, which may enhance patient satisfaction and usage rates.
- Industry Influence: The NCC, held biennially, attracts vision professionals from around the globe, and CooperVision's participation not only showcases its leadership in the industry but may also drive further development in the contact lens market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 75.820
Low
73.00
Averages
90.33
High
100.00
Current: 75.820
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Price Fluctuation Analysis: COO stock has a 52-week low of $61.775 and a high of $89.66, with the last trade at $74.20, indicating significant price volatility within this range and reflecting market caution towards the stock.
- Technical Indicator Reference: Data from TechnicalAnalysisChannel.com mentions COO's 200-day moving average, suggesting that investors should monitor this indicator to assess future price trends and make informed investment decisions.
- Market Sentiment Observation: Although the current stock price is positioned in the middle of the 52-week range, mixed market perceptions of COO may influence investor confidence and buying decisions.
- Investor Focus Points: Investors should pay attention to COO's technical analysis and market dynamics to make more informed investment choices amid price fluctuations.
See More
- Market Weakness: The S&P 500 index fell by 1.33%, and the Dow Jones Industrial Average hit a 3.5-month low, reflecting investor concerns over the Middle East conflict potentially driving energy prices higher and sparking inflation risks, which dampens market confidence.
- Disappointing Employment Data: The US nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a weakening labor market that raises doubts about economic health and may lead the Fed to adopt a more cautious approach in future policy adjustments.
- Surge in Energy Prices: WTI crude oil prices surged over 12% to a 2.5-year high as the ongoing Middle East conflict exacerbates supply concerns, which is expected to push global oil prices even higher, impacting profitability across related sectors.
- Corporate Earnings Resilience: Despite the overall market decline, 74% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, demonstrating a degree of resilience among businesses that may support future market recovery.
See More
- Market Decline: The S&P 500 index fell by 0.95%, the Dow Jones Industrial Average by 1.00%, and the Nasdaq 100 by 0.76%, reflecting market concerns that the ongoing Middle East war could drive energy prices higher, leading to inflation.
- Weak Employment Data: U.S. nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a deteriorating labor market and exacerbating fears of an economic slowdown.
- Surge in Energy Prices: WTI crude oil prices surged over 9% to a 2.25-year high due to the ongoing conflict in the Middle East, raising inflation expectations and diminishing investor confidence in the stock market.
- Corporate Earnings Performance: Despite the overall market weakness, 73% of S&P 500 companies exceeded earnings expectations, with Q4 earnings projected to grow by 8.4%, demonstrating resilience among some firms that may provide future market support.
See More
- Bank Stocks Decline: All 101 stocks in the State Street SPDR S&P Bank ETF (KBE) fell on Friday as the spread between the 2- and 10-year Treasury yields widened, with Western Alliance Bancorp down nearly 12%, indicating rising future inflation expectations that could compress banks' net interest margins and increase credit risk.
- Fertilizer Stocks Rally: Fertilizer stocks surged again due to tight supplies from the Iran conflict, with CF Industries climbing 5% to a new 52-week high and a week-to-date gain of about 17%, reflecting strong market expectations for fertilizer demand amid geopolitical tensions.
- Airline Stocks Under Pressure: United Airlines shares tumbled nearly 4% after CEO Scott Kirby warned that rising fuel prices would have a
See More
- Market Decline: The S&P 500 index fell by 1.68%, with the Dow Jones Industrial Average hitting a 3.5-month low, reflecting market concerns that the Middle East war could drive energy prices higher, leading to inflation risks.
- Weak Labor Market: U.S. nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a labor market health below expectations, which could slow consumer spending and impact economic growth.
- Surging Energy Prices: Amid escalating tensions in the Middle East, WTI crude prices surged over 7% to a 2.25-year high, likely pushing global fuel prices higher, which could affect airline profits and consumer spending.
- Optimistic Corporate Earnings: Despite market volatility, over 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, indicating strong corporate profitability, and S&P 500 earnings growth is projected to reach 8.4% for Q4.
See More
- Earnings Beat: Cooper Companies reported Q1 earnings of $1.10 per share, exceeding the analyst consensus of $1.03, indicating strong operational performance despite slight sales shortfall.
- Sales Miss: The company reported quarterly sales of $1.024 billion, slightly below the expected $1.026 billion, highlighting competitive pressures in certain market segments.
- Guidance Raised: Cooper Companies raised its FY2026 adjusted EPS guidance from $4.45-$4.60 to $4.58-$4.66, and increased sales guidance from $4.299 billion-$4.338 billion to $4.306 billion-$4.346 billion, reflecting management's confidence in future performance.
- Analyst Rating Changes: Following the earnings announcement, Needham analyst raised the price target from $99 to $101, Barclays from $98 to $103, while Citigroup lowered its target from $88 to $87, indicating varied market perspectives on Cooper Companies' outlook.
See More











